Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.17 Consensus Price Target from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $62.17.

CLDX has been the topic of several recent analyst reports. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, June 18th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 3rd. Finally, Wolfe Research started coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 target price on the stock.

Read Our Latest Analysis on CLDX

Celldex Therapeutics Trading Down 1.5 %

NASDAQ:CLDX opened at $36.63 on Friday. The firm has a market cap of $2.41 billion, a P/E ratio of -12.85 and a beta of 1.58. The stock has a 50 day moving average of $36.98 and a two-hundred day moving average of $39.24. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.30 million. On average, research analysts forecast that Celldex Therapeutics will post -2.39 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Samuel Bates Martin sold 35,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the transaction, the chief financial officer now owns 25,128 shares in the company, valued at approximately $855,608.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Samuel Bates Martin sold 35,000 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $34.05, for a total value of $1,191,750.00. Following the sale, the chief financial officer now owns 25,128 shares of the company’s stock, valued at $855,608.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares in the company, valued at approximately $305,249.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 266,332 shares of company stock valued at $9,155,821. Insiders own 3.80% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its stake in Celldex Therapeutics by 48.9% in the 4th quarter. BNP Paribas Financial Markets now owns 136,601 shares of the biopharmaceutical company’s stock valued at $5,418,000 after purchasing an additional 44,878 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Celldex Therapeutics by 5.9% in the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock valued at $149,484,000 after buying an additional 300,406 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Celldex Therapeutics by 16.3% during the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after buying an additional 427,827 shares during the period. Point72 Asset Management L.P. boosted its position in Celldex Therapeutics by 105.3% during the fourth quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock worth $109,308,000 after acquiring an additional 1,413,722 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Celldex Therapeutics by 13.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock worth $16,236,000 after acquiring an additional 47,844 shares during the period.

Celldex Therapeutics Company Profile

(Get Free Report

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Recommended Stories

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.